ロード中...
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
BACKGROUND: The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients. METHODS:...
保存先:
| 出版年: | J Crohns Colitis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8083188/ https://ncbi.nlm.nih.gov/pubmed/33884425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab071 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|